Hans Mg Princen

List of Publications by Year
in descending order

33 papers	2,688 citations	257450 24 h-index	414414 32 g-index
33 all docs	33 docs citations	33 times ranked	3655 citing authors

#	Article	IF	Citations
1	Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 211-221.	27.0	633
2	Supplementation With Low Doses of Vitamin E Protects LDL From Lipid Peroxidation in Men and Women. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 325-333.	2.4	197
3	The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. European Heart Journal, 2017, 38, 2499-2507.	2.2	176
4	Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. Journal of Lipid Research, 2014, 55, 2103-2112.	4.2	165
5	Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein inAPOE*3Leiden.CETPMice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 2016-2022.	2.4	161
6	Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterolâ€“Lowering Effect in APOE*3-Leiden Transgenic Mice. Circulation, 2003, 108, 1368-1374.	1.6	157
7	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor-îœ€. Blood, 1999, 93, 2991-2998.	1.4	127
8	Perfluoroalkyl Sulfonates Cause Alkyl Chain Lengthâ€“Dependent Hepatic Steatosis and Hypolipidemia Mainly by Impairing Lipoprotein Production in APOE*3-Leiden CETP Mice. Toxicological Sciences, 2011, 123, 290-303.	3.1	118
9	Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis, 1996, 122, 245-253.	0.8	104
10	Torcetrapib Does Not Reduce Atherosclerosis Beyond Atorvastatin and Induces More Proinflammatory Lesions Than Atorvastatin. Circulation, 2008, 117, 2515-2522.	1.6	89
11	Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. Journal of Lipid Research, 2007, 48, 1763-1771.	4.2	86
12	Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis, 2008, 197, 57-63.	0.8	76
13	Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?. Atherosclerosis, 1998, 140, 15-24.	0.8	67
14	PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE. Journal of Lipid Research, 2014, 55, 2370-2379.	4.2	59
15	Increased Fecal Bile Acid Excretion in Transgenic Mice With Elevated Expression of Human Phospholipid Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 892-897.	2.4	56
16	Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice. Journal of Nutritional Biochemistry, 2013, 24, 1423-1430.	4.2	49
17	Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. Journal of Lipid Research, 2020, 61, 365-375.	4.2	48
18	Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials. European Journal of Pharmacology, 2015, 763, 48-63.	3.5	44

#	Article	IF	Citations
19	Fibrates Suppress Fibrinogen Gene Expression in Rodents Via Activation of the Peroxisome Proliferator-Activated Receptor-îœ€. Blood, 1999, 93, 2991-2998.	1.4	39
20	Salsalate attenuates diet induced nonâ€alcoholic steatohepatitis in mice by decreasing lipogenic and inflammatory processes. British Journal of Pharmacology, 2015, 172, 5293-5305.	5.4	29
21	Fenofibrate Increases Very Low Density Lipoprotein Triglyceride Production Despite Reducing Plasma Triglyceride Levels in APOE*3-Leiden.CETP Mice. Journal of Biological Chemistry, 2010, 285, 25168-25175.	3.4	28
22	Olmesartan and pravastatin additively reduce development of atherosclerosis in APOE*3Leiden transgenic mice. Journal of Hypertension, 2007, 25, 2454-2462.	0.5	27
23	Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. Journal of Hypertension, 2012, 30, 107-116.	0.5	27
24	Anacetrapib reduces (V)LDL cholesterol by inhibition of CETP activity and reduction of plasma PCSK9. Journal of Lipid Research, 2015, 56, 2085-2093.	4.2	27
25	Effect of methylglyoxal on the physico-chemical and biological properties of low-density lipoprotein. Lipids and Lipid Metabolism, 1998, 1394, 187-198.	2.6	23
26	Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. Biochemical Pharmacology, 2012, 84, 821-829.	4.4	21
27	Absence of an atheroprotective effect of the garlic powder printanor in APOE*3-Leiden transgenic mice. Atherosclerosis, 2004, 177, 291-297.	0.8	13
28	Seasonal Variation in Low Density Lipoprotein Oxidation and Antioxidant Status. Free Radical Research, 1997, 27, 89-96.	3.3	11
29	Comment on â€œHypercholesterolemia with consumption of PFOA-laced Western diets is dependent on strain and sex of miceâ€•by Rebholz S.L. et al. Toxicol. Rep. 2016 (3) 46â€“54. Toxicology Reports, 2016, 3, 306-309.	3.3	11
30	Oxidation of LDL and extent of peripheral atherosclerosis. Free Radical Research, 1999, 31, 129-139.	3.3	10
31	Plasma coenzyme Q10concentrations are not decreased in male patients with coronary atherosclerosis. Free Radical Research, 1999, 30, 165-172.	3.3	6
32	No effects of PCSK9-inhibitor treatment on spatial learning, locomotor activity, and novel object recognition in mice. Behavioural Brain Research, 2021, 396, 112875.	2.2	3
33	Modification of Low-Density Lipoprotein by Methylglyoxal Alters its Physico-Chemical and Biological Properties. , 2005, , 285-290.		1